Expression of a novel CNPY2 isoform in colorectal cancer and its association with oncologic prognosis

Peng, Jianhong; Ou, Qingjian; Jian, Guo; Pan, Zhizhong; Zhang, Rongxin; Wu, Xiaojun; Zhao, Yujie; Deng, Yuxiang; Li, Caixia; Xu, Rui-Hua; Li, Liren; Chen, Gong; Lu, Zhenhai; Ding, Pei-Rong; Wan, Desen; Fang, Yujing

doi:10.18632/aging.101324

Cited by 10 publications

(13 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, CNPY2 isoform 2 was identified as a novel biomarker in oncologic research by examination of its expression in CRC cell lines and tissues [ 17 ]. In the current study, we further focused on the detection of serum CNPY2 isoform 2 in CRC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, we previously assessed the associations between CNPY2 isoform 2 expression and various clinicopathological parameters, including tumor size and clinical stage. As a result, no significant association was found between CNPY2 isoform 2 expression with the above clinicopathological characteristics [ 17 ]. We considered that serum CNPY2 isoform 2 might have been significantly up-regulated in the early stages of tumorigenesis but not in the tumor progression.…”

Section: Discussionmentioning

confidence: 99%

“…Purified recombinant CNPY2 isoform 2 proteins and the monoclonal antibody clones were generated, and five effective monoclonal antibody clones were selected by using immunohistochemistry (IHC) as we previously reported [ 17 ]. Based on these five selected monoclonal antibody clones, a sandwich ELISA kit for CNPY2 isoform 2 was developed by Senboll Biotechnology Co., Ltd., using a pair of monoclonal antibodies.…”

Section: Methodsmentioning

confidence: 99%

“…Compared to CNPY2 isoform 1, CNPY2 isoform 2 has a homogeneous region in the first 69 amino acids but possesses a different C-terminal. Our previous study first found that CNPY2 isoform 2 was a novel biomarker that is highly expressed in the cytoplasm of CRC cells and associated with CRC prognosis [ 17 ]. Based on an amino acid sequence analysis, CNPY2 isoform 2 has a signal peptide in the first 20 amino acids and does not contain any transmembrane domains, suggesting that it functions as a secreted protein.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer

Peng

Pan

et al. 2018

Aging

Self Cite

View full text Add to dashboard

Since early diagnosis is very important for treating CRC, we decided to detect peripheral serum canopy fibroblast growth factor signaling regulator 2 (CNPY2) isoform 2 to verify its diagnostic value for CRC patients. Serum samples were collected from 430 CRC patients and 201 healthy controls. Enzyme-linked immunosorbent assay (ELISA) detection kits for CNPY2 isoform 2 were generated and then applied to measure serum CNPY2 isoform 2 concentrations. Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were also measured. The median serum CNPY2 isoform 2 concentrations in all CRC patients were significantly higher than those in the healthy control group (all P<0.001). Those with stage I CRC presented the highest area under the receiver operating characteristic curve (AUC) for CNPY2 isoform 2 [0.707, 95% confidence interval (CI): 0.649–0.765, P<0.001]. The diagnostic efficiency of the combination of CNPY2 isoform 2, CEA and CA19-9 was significantly higher than that of each biomarker detected separately (all P<0.0167). Serum CNPY2 isoform 2 may be a valuable biomarker for the early detection of CRC and presents an improvement in the diagnostic efficiency by combination of CEA and CA19-9.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer

Peng

Pan

et al. 2018

Aging

Self Cite

View full text Add to dashboard

show abstract

“…The development of distant metastasis is the main reason of cancer-related death regardless of effective surgical procedures and systemic chemotherapy. Approximately 20–25% of patients are initially diagnosed with synchronous metastases, of which approximately 50% ultimately develop metachronous disease after colectomy [3, 4]. The survival outcome of CRC is mainly determined by tumor stage and some other clinicopathological factors.…”

Section: Introductionmentioning

confidence: 99%

High expression of MMP19 is associated with poor prognosis in patients with colorectal cancer

Chen

et al. 2019

BMC Cancer

View full text Add to dashboard

Background Matrix metalloproteinase 19 (MMP19) is a member of zinc-dependent endopeptidases, which have been involved in various physiological and pathological processes. Its expression has been demonstrated in some types of cancers, but the clinical significance of MMP19 in colorectal cancer (CRC) has not been reported. Thus, we aimed to analyze the clinical significance of MMP19 in CRC in present study. Methods The expression of MMP19 was first explored in The Cancer Genome Atlas (TCGA) cohort, and then validated in the GSE39582 cohort and our own database. Clinicopathological features and survival rate were also investigated. Results MMP19 was found to be a predictor for overall survival (OS) in both univariate (hazard ratio [HR]: 1.449, 95% confidence interval [CI]: 1.108–1.893, P = 0.007) and multivariate survival analyses (HR: 1.401, 95% CI: 1.036–1.894, P = 0.028) in the TCGA database. MMP19 was further validated as an independent factor for recurrence free survival in the GSE39582 database by both univariate analysis (HR: 2.061, 95%CI: 1.454–2.921, P < 0.001) and multivariate analysis (HR = 1.470, 95% CI: 1.025–2.215, P = 0.032 ). In an in-house cohort, MMP19 was significantly upregulated in CRC tissues when compared with their adjacent normal controls ( P < 0.001). Ectopic MMP19 expression was positively associated with lymph node metastases ( P = 0.029), intramural vascular invasion ( P = 0.015) and serum carcinoembryonic antigen levels ( P = 0.045). High MMP19 expression correlated with a shorter OS (HR = 5.595; 95% CI: 2.573–12.164; P < 0.001) and disease free survival (HR = 4.699; 95% CI: 2.461–8.974; P < 0.001) in multivariate cox regression analysis. Conclusions Expression of MMP19 was upregulated in CRC. High expression of MMP19 was determined to be an independent and poor prognostic factor in CRC. These results suggest that MMP19 may be a good biomarker for CRC.

show abstract

Expression of a novel CNPY2 isoform in colorectal cancer and its association with oncologic prognosis

Cited by 10 publications

References 26 publications

Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer

Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer

High expression of MMP19 is associated with poor prognosis in patients with colorectal cancer

Contact Info

Product

Resources

About